Last updated September 9, 2026
Key finding
MI treatment was associated with a significant reduction of GDM (aRR: 0.58, 0.36, 0.91, p = 0.020).
This study investigated the effect of Myo-Inositol on preventing gestational diabetes mellitus (GDM) and found a significant reduction in GDM incidence.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effect of Myo-Inositol on preventing gestational diabetes mellitus (GDM) and found a significant reduction in GDM incidence.
Gestational diabetes mellitus can lead to serious health issues for both mothers and babies. By demonstrating that Myo-Inositol can significantly reduce the incidence of GDM, this study provides evidence for a potential preventive treatment that could improve maternal and fetal health outcomes. This finding is particularly relevant for healthcare providers looking to mitigate risks associated with pregnancy.
Limited generalizability due to specific population characteristics. Potential confounding factors not measured. Small sample size may affect the robustness of findings.
Published in
Publication details and source links for this paper.
Ashraf M, Mahboobeh S, Mahdi S, et al. The Effect of Myo-Inositol on the Prevention of Gestational Diabetes Mellitus: A Randomized Controlled Trial. International Journal of Reproductive Biomedicine. 2025;23(4):323-332. doi:10.18502/ijrm.v23i4.18784
Myo-Inositol treatment significantly reduced GDM incidence (aRR: 0.58, p = 0.020).
No significant difference in macrosomia incidence between the two groups.
No significant difference in pre-eclampsia incidence between the two groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Myo-inositol plus folic acid, Placebo plus folic acid and Gestational diabetes mellitus incidence, Incidence of macrosomia, Intrauterine growth restriction incidence, and 3 more.
This study contributes evidence to
Primary intervention
Myo-inositol plus folic acid
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
12
Evidence pairs
49
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Myo-inositol plus folic acid → Gestational diabetes mellitus incidence
Myo-inositol plus folic acid → Gestational diabetes mellitus incidence
Myo-inositol plus folic acid → Incidence of macrosomia
Myo-inositol plus folic acid → Incidence of macrosomia
Myo-inositol plus folic acid → Intrauterine growth restriction incidence
Myo-inositol plus folic acid → Intrauterine growth restriction incidence
Myo-inositol plus folic acid → Maternal pre-eclampsia
Myo-inositol plus folic acid → Maternal pre-eclampsia
Myo-inositol plus folic acid → Mode of delivery outcomes
Myo-inositol plus folic acid → Mode of delivery outcomes
Myo-inositol plus folic acid → Rate of preterm delivery (<37 weeks)
Myo-inositol plus folic acid → Rate of preterm delivery (<37 weeks)
Placebo plus folic acid → Gestational diabetes mellitus incidence
Placebo plus folic acid → Gestational diabetes mellitus incidence
Placebo plus folic acid → Incidence of macrosomia
Placebo plus folic acid → Incidence of macrosomia
Placebo plus folic acid → Intrauterine growth restriction incidence
Placebo plus folic acid → Intrauterine growth restriction incidence
Placebo plus folic acid → Maternal pre-eclampsia
Placebo plus folic acid → Maternal pre-eclampsia
Placebo plus folic acid → Mode of delivery outcomes
Placebo plus folic acid → Mode of delivery outcomes
Placebo plus folic acid → Rate of preterm delivery (<37 weeks)
Placebo plus folic acid → Rate of preterm delivery (<37 weeks)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Myo-inositol plus folic acid and Diabetes Incidence and Prevention, Myo-inositol plus folic acid and Incidence of macrosomia.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Diabetes Incidence and Prevention
Measures Diabetes Incidence and Prevention as a key outcome.
All studies measuring Incidence of macrosomia
Measures Incidence of macrosomia as a key outcome.
All studies on Myo-inositol plus folic acid
Contributes to Myo-inositol plus folic acid evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Myo-inositol plus folic acid appears to reduce gestational diabetes mellitus incidence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Gestational diabetes mellitus incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear reduction in incidence of macrosomia with Myo-inositol plus folic acid.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incidence of macrosomia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear reduction in intrauterine growth restriction incidence with Myo-inositol plus folic acid.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Intrauterine growth restriction incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Myo-inositol plus folic acid for maternal pre-eclampsia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Maternal pre-eclampsia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
